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Abstract
Background: Lisdexamfetamine Dimesylate (LDX) is a therapeutically inactive amphetamine prodrug.
Pharmacologically active d-amphetamine is released from Lisdexamfetamine following oral ingestion. It is
indicated in the treatment of children ages 6-12 with Attention Deficit Hyperactivity Disorder (ADHD). The
goal of LDX is to provide a one dose, extended release medication throughout the day as well as a reduced
potential for abuse, overdose toxicity and drug misuse.
Hypothesis: Evaluation of the Efficacy and Tolerability of Lisdexamfetamine Dimesylate (Vyvanse) in
Treating Children Age 6-12 with Attention Deficit Hyperactivity Disorder
Study Design: Extensive search of available medical literature and review regarding LDX efficacy and
tolerability in children ages 6-12 with ADHD.
Methods: Exhaustive literature search using the following search engines: MEDLINE, Evidence Based
Medicine Reviews Multifile, CINAHL, Pub Med, MD Consult, And PsycINFO. The main inclusion criteria
were: children age 6-12, patients taking single therapy Lisdexamfetamine dimesylate, primary diagnosis of
ADHD based on a psychiatric evaluation that reviews DSM-IV criteria. The exclusion criteria for the study
were: comorbid psychiatric diagnoses (such as psychosis, bipolar illness, pervasive developmental disorder,
severe obsessive compulsive disorder, and severe depressive or severe anxiety disorder), adolescent or adults
and patients currently taking alternative amphetamines.
Results: Biederman et al, Study A: Significant improvements in ADHD-RS-IV scores were seen with all doses
of LDX compared with placebo (all, P<0.0001), and in CPRS scores with all LDX doses versus placebo
throughout the day (all, P<0.0001 for all comparisons). Efficacy was observed by the first week of treatment
and improvements were observed throughout the day up to 6pm. Biederman et al, Study B: LDX treatment
significantly improved scores on SKAMP-Deportment, and Attention, PERMP attempted and correct and
CGI improvement from baseline. Adverse events were similar for both active treatments. Wigal et al, Study C:
Compared with placebo, LDX demonstrated significantly greater efficacy at each post-dose time point (1.5
hours to 13 hours), as measured by SKAMP-Deportment and attention scale and PERMP (P < 0.005). The
most common adverse effects during dose optimization were: decreased appetite, insomnia, headache,
irritability, upper abdominal pain and affect lability, which were less frequent in the crossover phase. Findling
et al, Study D: From baseline to endpoints, mean ADHD-RS score improved 27.2 points (P <0.0001).
Improvements occurred during each of the first 4 weeks, and were maintained throughout. Based on CGI
improvement scale scores, >80% of subjects at endpoint and >95% of completers at 12 months were rated
“improved”. Most adverse events were mild to moderate and occurred during the first 4 weeks. There were no
clinically meaningful changes in blood pressure or ECG.
Conclusion: In school aged children ages 6-12 with ADHD, LDX a long acting prodrug of D-amphetamine,
has been reported to be effective in improving ADHD symptoms throughout the school day and into the early
evening with a once daily dose. Additional long term, non bias and comparison studies are needed to evaluate
the efficacy and tolerability with prolonged use.
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Abstract   
 
Background:  Lisdexamfetamine Dimesylate (LDX) is a therapeutically inactive 
amphetamine prodrug. Pharmacologically active d-amphetamine is released from 
Lisdexamfetamine following oral ingestion. It is indicated in the treatment of children 
ages 6-12 with Attention Deficit Hyperactivity Disorder (ADHD). The goal of LDX is to 
provide a one dose, extended release medication throughout the day as well as a reduced 
potential for abuse, overdose toxicity and drug misuse.  
 
Hypothesis:  Evaluation of the Efficacy and Tolerability of Lisdexamfetamine 
Dimesylate (Vyvanse) in Treating Children Age 6-12 with Attention Deficit 
Hyperactivity Disorder 
 
Study Design:  Extensive search of available medical literature and review regarding 
LDX efficacy and tolerability in children ages 6-12 with ADHD. 
 
Methods:  Exhaustive literature search using the following search engines: MEDLINE, 
Evidence Based Medicine Reviews Multifile, CINAHL, Pub Med, MD Consult, And 
PsycINFO. The main inclusion criteria were: children age 6-12, patients taking single 
therapy Lisdexamfetamine dimesylate, primary diagnosis of ADHD based on a 
psychiatric evaluation that reviews DSM-IV criteria. The exclusion criteria for the study 
were: comorbid psychiatric diagnoses (such as psychosis, bipolar illness, pervasive 
developmental disorder, severe obsessive compulsive disorder, and severe depressive or 
severe anxiety disorder), adolescent or adults and patients currently taking alternative 
amphetamines. 
 
Results:  Biederman et al, Study A: Significant improvements in ADHD-RS-IV scores 
were seen with all doses of LDX compared with placebo (all, P<0.0001), and in CPRS 
scores with all LDX doses versus placebo throughout the day (all, P<0.0001 for all 
comparisons). Efficacy was observed by the first week of treatment and improvements 
were observed throughout the day up to 6pm. 1Biederman et al, Study B: LDX treatment 
significantly improved scores on SKAMP-Deportment, and Attention, PERMP attempted 
and correct and CGI improvement from baseline. Adverse events were similar for both 
active treatments.2 Wigal et al, Study C: Compared with placebo, LDX demonstrated 
significantly greater efficacy at each post-dose time point (1.5 hours to 13 hours), as 
measured by SKAMP-Deportment and attention scale and PERMP (P < 0.005). The most 
common adverse effects during dose optimization were: decreased appetite, insomnia, 
headache, irritability, upper abdominal pain and affect lability, which were less frequent 
in the crossover phase.3 Findling et al, Study D: From baseline to endpoints, mean 
ADHD-RS score improved 27.2 points (P <0.0001). Improvements occurred during each 
of the first 4 weeks, and were maintained throughout. Based on CGI improvement scale 
scores, >80% of subjects at endpoint and >95% of completers at 12 months were rated 
“improved”. Most adverse events were mild to moderate and occurred during the first 4 
weeks. There were no clinically meaningful changes in blood pressure or ECG.4 
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Conclusion:  In school aged children ages 6-12 with ADHD, LDX a long acting prodrug 
of D-amphetamine, has been reported to be effective in improving ADHD symptoms 
throughout the school day and into the early evening with a once daily dose. Additional 
long term, non bias and comparison studies are  needed to evaluate the efficacy and 
tolerability with prolonged use. 
 
Keywords: Attention Deficit Hyperactivity Disorder, Children, Lisdexamfetamine 
Dimesylate, Vyvanse, NRP-104, stimulant, and amphetamine. 
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Evaluation of the Efficacy and Tolerability of Vyvanse 
(Lisdexamfetamine Dimesylate) in Treating Children 
Age 6-12 with Attention Deficit Hyperactivity Disorder 
 
Introduction  
Attention deficit hyperactivity disorder (ADHD) is one of the most common 
neurobehavioral disorders of childhood and adolescence. It is estimated to affect 8%-12% 
of children worldwide.1 Typically it is first diagnosed in childhood and the symptoms 
often persist into adolescence and adulthood. According to the American Psychiatric 
Association’s Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, 
Test Revision (DSM-IV-TR) (Table I), ADHD is characterized by inattention, 
hyperactivity and impulsivity developing before the age of 7 that are both, more severe 
and more frequent, than commonly observed in children at a similar developmental level. 
15 The symptoms of ADHD can cause significant impairments throughout one’s life if left 
untreated. A comorbid condition is present in as many as two thirds of clinically referred 
children with ADHD, this makes diagnosis and treatment very difficult6. The origin and 
risk factors for ADHD are unknown, but researchers are finding that genetics play a key 
role.  
Medications to treat ADHD historically included stimulants, most commonly, 
methylphenidate (MPH) and amphetamines (AMP) .7 MPH and AMP, both stimulant 
medications, have the most evidence for efficacy and safety in the treatment of ADHD 
and remain the first line pharmacological intervention for ADHD. 8 In 2002, a non-
stimulant option, Amoxetine was approved by the FDA.7  Medications used to treat 
ADHD are most successful when combined with psychotherapy, behavioral management, 
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classroom and home strategies that support children with ADHD.76 The stimulant class of 
medications helps reduce hyperactivity and impulsivity while improving the ability to 
focus, work and learn.8 They come in various forms ranging from: short-acting, long-
acting, extended release capsules, pills, liquid and skin patch. The efficacies of these 
various forms of stimulants have been well studied and established in improving ADHD 
symptoms. Stimulants are considered to be the most researched medication in children 
and have been shown to expand children’s academic performance over the years.6 
Nevertheless, there continue to be areas regarding the effectiveness of the current 
stimulants that are problematic. For example, adverse effects of stimulants: decreased 
appetite, sleep disturbances, headache and upper abdominal pain. Another area of 
concern around stimulants is multi-dosing throughout the day, inadequate control of the 
duration of action, and potential for abuse. These problematic areas motivate researchers 
to develop a more tolerated form of medication to help treat ADHD. There is no cure for 
ADHD, but these medications can help individuals become more successful in school and 
manage a productive life. Effective treatment of ADHD that will achieve an optimal 
therapeutic response and an appropriate duration of action, along with patient satisfaction 
and compliance are difficult. This fine balance involves taking into consideration the 
specific needs of the patient, the characteristics of the individual patient, the formulation 
of the stimulant or non-stimulant and their delivery method.  
Lisdexamfetamine Dimesylate (LDX) is a prodrug of dextroamphetamine, a 
stimulant that was approved by the FDA in February 2007 for the treatment of attention 
deficit hyperactivity disorder (ADHD).9 LDX is the first prodrug stimulant to be 
developed. It is a therapeutically inactive prodrug made up of l-lysine amino acid 
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covalently bonded to d-amphetamine (dextroamphetamine).9 After oral ingestion it is 
activated by being converted into dextroamphetamine in the gastrointestinal tract. 10Thus 
it is not converted to the active form if injected or inhaled, thereby limiting the potential 
for abuse. It has been developed to have similar efficacy to that of current extended-
release central stimulants with reduced potential for abuse, overdose toxicity, and drug 
tampering.11  
Objective 
This article reviews the literature regarding the development and use of 
Lisdexamfetamine Dimesylate (LDX, Vyvanse) in treating children age 6-12 with 
attention deficit hyperactivity disorder (ADHD). The results of the literature search 
appear in Table II. 
Methods 
An exhaustive literature search using the following search engines was 
performed: MEDLINE, Evidence Based Medicine Reviews Multifile, CINAHL, Pub 
Med, MD Consult, and PsycINFO. The literature search was performed using the 
following search terms. Attention deficit hyperactivity disorder, Children, 
Lisdexamfetamine Dimesylate, Vyvanse, NRP-104, and stimulant. 
The criteria for inclusion of a study were children ages 6-12, diagnoses of ADHD 
defined by DSM-IV, and patients taking single therapy Lisdexamfetamine to treat their 
ADHD. The criteria for exclusion of a study were comorbid psychiatric diagnoses, 
adolescents, adults, combination therapy. 
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Results 
Study A 
Biederman et al (study A), a phase III, multicenter, randomized, double blinded, 
forced-dose, parallel-group study was supported by New River Pharmaceuticals Inc. and 
Shire Development Inc. (Table II) This study has a calculated Jadad score five. The study 
randomized 290 patients  in a 1:1:1:1 ratio, using a computer generated randomization 
schedule to receive double-blind, oral capsules of LDX 30mg for 4 weeks, 50mg (30mg/d 
for week 1, with forced dose escalation to 50mg/d for weeks 2-3), or 70mg (30mg/d for 
week 1, with forced dose escalation to 50mg/d for week 2 and 70mg/d for weeks 3 and 
4), or placebo capsules for 4 weeks.  Of the participants’ 201were boys, 89 were girls, the 
mean age was 9 years and they all have a DSM-IV diagnosis of ADHD.1 
ADHD symptoms were assessed using parent and investigator completed rating 
scales. (Table III) The efficacy of LDX was assessed using the ADHD Rating Scale 
Version IV (ADHD-RS-IV), the Conners [SIC] Parent Rating Scale (CPRS) and the 
Clinical Global Impression of Improvement Scale (GCI). Tolerability was assessed 
throughout this study by evaluating adverse events, ECG, physical examination and 
clinical laboratory tests.1 
Out of the 297 children enrolled seven children discontinued before 
randomization, 290 received the randomized and blinded treatment, 285 were included in 
the Intent to treat (ITT) population, 230 completed the study (LDX 30mg n = 56; LDX 
50mg n = 60; LDX 70mg n = 60 and placebo n = 54). 60 participants were withdrawn 
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before the study completion most commonly due to lack of drug efficacy (LDX 30mg 
=1%, LDX 50mg = 0%, LDX 70mg = 1% and placebo = 17%) and adverse events (LDX 
30mg = 9%, LDX 50mg = 5%, LDX 70mg = 14% and placebo = 1%). Treatment 
compliance was 84% in the randomized population for all 4 treatment weeks.1 
Primary Efficacy 
Primary efficacy was measured by the change from baseline to end point by the 
attention deficit hyperactivity disorder-rating scale-fourth edition (ADHD-RS-IV) total 
score. The ADHD-RS-IV total score was significantly greater with each of the 3 
Lisdexamfetamine (LDX) doses compared with placebo (P<0.001). The largest mean 
reduction in ADHD-RS-IV score was in the 70mg group. During the first week after all 
treated patients received LDX 30mg, ADHD-RS-IV scores were significantly improved 
compared with placebo and continued to improve over the 4 week period. All LDX 
groups compared with placebo showed greater improvement in both the ADHD-RS-IV 
Inattention and Hyperactivity subscales from baseline to end point (all, P < 0.001). Dose 
comparisons showed the difference in least squares (LS) mean ADHD-RS-IV change 
from baseline scores between the 30 and 70mg groups was – 4.91 (P < 0.05).1  
Secondary Efficacy 
The Conners Parent Rating Scale-Revised: short form (CPRS-Revised), is a 
parent rated scale designed to assess the symptomatic behaviors of ADHD. (Table II) 
This scale was used to evaluate participants at 10am, 2pm and 6pm. The CPRS 
comprised of 27 questions grouped into 4 subscales: Oppositional, Cognitive Problems, 
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Hyperactivity and ADHD index. Based on CPRS-Revised scores, beginning after 
appropriate dose titration and continuing throughout the study (P < 0.01), 
parents/guardians of patients in each LDX dose group reported significantly greater 
improvement in symptom control throughout the day. The CPRS-Revised was used to 
assess symptoms in the morning (10 AM), afternoon (2 PM) and evening (6 PM) 
compared with placebo (P < 0.01). Again those taking the 70mg LDX dose showed the 
most improvement of the CPRS-Revised scores compared with placebo.1  
Clinical Global Impressions 
Clinical Global Impressions (CGI) scale scores are used to measure symptom 
severity, treatment response and the efficacy of treatments in therapy studies.(Table III) 
The scale is used by clinicians and has a seven point rating scale (1= very much 
improved, 7= very much worse). ADHD symptom severity was measured by the CGI 
scale at baseline and then was reassessed as following visits. In this study the GCI-
improvement scale showed a considerably greater improvement from starting to finishing 
treatment for all active treatment groups compared with placebo (all, P <0.001). CGI-
Improvement scale ratings which clinicians rate the illnesses development compared to 
base line. A score of 1 is very much improved and 7 are very much worse. Participants 
CGI-Improvement rate were “very much improved” (CGI-I score 1) or “much improved” 
(CGI-I score 2) in ≥ 70% of treatment group patients, compared to 18% of placebo 
patients. 1 
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Adverse Events 
Adverse events were experienced by each of the treatment groups (LDX 30mg = 
72%, LDX 50mg = 68%, LDX = 84% and placebo = 47%). (Table IV) The adverse 
events experienced while talking LDX are commonly seen with amphetamine use. More 
than 95% of adverse effects requiring treatment were considered mild to moderate in 
intensity. The adverse effects were commonly noticed during the first week and then 
slowly disappeared. No serious adverse effects were demonstrated. Adverse effects 
observed with LDX and placebo use were: decreased appetite (39% with LDX vs. 4% 
with placebo; P ≤ 0.05), insomnia (19% vs. 3%; P ≤0.05), upper abdominal pain (12% vs. 
6%; P=NS), headache (12% vs. 10% P = NS), irritability (10% vs. 0%; P ≤ 0.05), 
vomiting (9% vs. 4%, P = NS), weight loss (9% vs. 1%; P ≤ 0.05), and nausea (6% vs. 
3%; P = NS). 1 
Study B 
Biederman et al (study B) was an additional study evaluating the efficacy, safety 
and pharmacokinetic properties of LDX compared with placebo in the treatment of 
ADHD in children ages 6-12 with DSM-IV diagnosed ADHD (Table II). This was a 
phase II, randomized, multicenter, double-blinded, placebo and active controlled, 
crossover study with mixed amphetamine salts extended release (MAS XR) included as a 
reference arm.  This study has a calculated Jadad score four. The study was supported by 
New River Pharmaceuticals Inc. and Shire Development Inc. 2 
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The efficacy portion was conducted in an analog classroom environment with 52 
participants (33 male, 19 female, mean ages 9.1) in 3 phases over 4 weeks at 4 study 
sites. Efficacy was measured by Swanson, Kotkin, Agler, M-Flynn, and Pelham 
(SKAMP) Deportment Rating Scale, Permanent Product Measure of Performance 
Attempted and Corrected (PERMP) and Clinical Global Impressions – Improvement 
(CGI-I) Scales. (Table III) SKAMP is scored on a seven point impairment scale ranging 
from zero to six, with higher scores indicating more severe ADHD symptoms. The 
SKAMP scores were completed by classroom evaluators for each subject during the 
classroom session of the assessment day. The PERMP, a validated 10 minute math test 
was developed to evaluate response to stimulant medications. It contains 400 age 
appropriate math problems and is scored to obtain an objective measure of academic 
performance by grading the number of attempted and completed problems. Both SKAMP 
and PERMP have been shown to be sensitive to dosage and time effects of stimulant 
medications. 2 
The study design comprised a 1) screening period (visit 1), 2) dose titration period 
(visits 2-5), 3) double blind crossover period (visits 6-4), 4) final study visit (visit 9) and 
5) 30-day telephone follow up. The school laboratory portion included an analog 
classroom and lasted for 13 hours. After screening and the washout period participants 
entered the dose titration period with open label administration of MAS XR for 3 weeks. 
The final dose of MAS XR at the end of the third titration week was considered the 
optimal daily dose and was used in the double blind phase to determine the dose of LDX 
subjects received. The participants were randomized by identical block-randomization 
schedules for all 3 cohorts after an open label dose adjustment period with MAS-XR, 
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which determined the optimal dose of LDX. Participants received all three treatments 
during this phase and the order of treatments was randomized. Cohort A (n = 10) received 
MAS-XR 10mg, LDX 30mg or Placebo for 1 week each, Cohort B (n = 17) received 
MAS-XR 20mg, LDX 50mg or Placebo for 1 week each and lastly Cohort C (n = 25) 
received MAS-XR 30mg, LDX 70mg or placebo for 1 week each (total of 3 weeks). At 
the end of each week evaluation of behavioral and safety parameters were assessed in a 
laboratory classroom.2  
Pharmacokinetics 
At the last visit of the study pharmacokinetics were measured. Cohort C was the 
largest group (n = 25) thus, making it the best measurement of pharmacokinetics. In 
Cohort C d-amphetamine from LDX reached median peak plasma levels in 4.5 hours and 
MAS XR at 6 hours. The mean Cmax value for d-amphetamine following MAS XR 30mg 
administration was 119 ± 52.5ng/ml. The mean Cmax value for d-amphetamine following 
LDX 70mg was 155 ± 31.4ng/ml.2  
Primary Efficacy 
Of the study participants treated with LDX, the mean SKAMP-Deportment score 
(primary efficacy measure) showed 0.8 ± 0.1 compared to placebo 1.7 ± 0.1 (P < 0.0001).  
The least squares (LS) mean SKAMP-Attention score for LDX was 1.2, compared to 
placebo of 1.8 (P < 0.0001).2 
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Secondary Efficacy 
PERMP-Attempted scores (response to stimulant) for LDX were 133.3 compared 
to placebo 88.2 (P < 0.0001). The LS mean PERMP-Correct scores for LDX were 129.6 
and 84.1 for placebo (P < 0.0001). In an analysis of PERMP ratings, this showed the 
duration of action of LDX (measured by the change in score at each hour beginning from 
1 hour after first dose) was favored in the population intended to treat at all time points 
(1, 2, 3, 4.5, 6, 8, 10 and 12 hours). The onset was observed to begin 2 hours after first 
dose compared to placebo.2 
Clinical Global Impressions 
On the CGI-Improvement scales LDX scores (2.2) indicated significant 
improvement compared with placebo (4.2) (P < 0.0001). Investigators rated 32% very 
much improved (CGI-I 1) and 42% much improved (CGI-I 2) of those LDX treated 
subjects compared to placebo at 18%.2 
Adverse Effects 
56% of participants complained of adverse effects, ranging from mild to moderate 
during the study, 16% of those were from LDX, 18% MAS-XR and 15% placebo. (Table 
IV) Adverse effects occurring at an incidence of > 2% while taking LDX during the 
double blinded treatment period were: insomnia (8%), decreased appetite (6%), and 
anorexia (4%). They claim that no serious adverse effects or deaths were reported in this 
study.2 
18 
 
Study C 
Wigal et al, a multicenter study was published in 2009 that assessed the initial 
onset and duration of efficacy of LDX compared with placebo (Table II). This study has a 
calculated Jadad score four. Grants for research were supported by Addrenex, Eli Lilly, 
McNeil, Psychogenics, Shire and NIMH. This study was comprised of 129 subjects, 98 
male, 91 female, mean ages 10.1, across 7 study sites over 10 weeks. The study design 
followed an open-label, dose-optimization of LDX (30, 50, 70mg daily for 4 weeks) 
followed by a randomized, placebo controlled, 2 way crossover phase (1 week each). 
Primary efficacy is measured by the SKAMP-Deportment scale and secondary efficacy is 
measured by the SKAMP-Attention and the PERMP attempted/corrected scales. These 
scales to measure efficacy were used before the first dose and at 1.5, 2.5, 5, 7.5, 10, 12 
and 13 hours after the first dose.3 
Primary Efficacy 
At 1.5 hours after the first dose and continuing through the measured time points 
including the 13 hour, LDX showed significant improvement on the SKAMP-
Deportment scale compared with placebo. At 12 and 13 hour after the first dose, 
SKAMP-Deportment scores were numerically worse but not statistically different from 
the predose levels. In the placebo group SKAMP-Deportment scores were worse than 
predose scores at all time points. There was significant separation in SKAMP-
Deportment scales of LDX from placebo at all post dose time points (P < 0.005 for all 
time points).3  
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Secondary Efficacy 
The results for PERMP-Attempted and PERMP-Correct were consistent with the 
results of SKAMP-Deportment. PERMP-Attempted and PERMP-Corrected scores were 
improved when evaluated at each post dose time (1.5-13hours). LDX also showed 
separation in PERMP-Attempted and Completed scores from placebo at these post dose 
times (P < 0.0001 for all points). At predose assessments least squares (LS) mean (SE) 
PERMP-Attempted and PERMP-Correct scores for LDX groups were [85.54 (4.88) and 
81.86 (4.84) respectively] compared to placebo [102.43 (4.880 and 99.17 (4.840) 
respectively; P < 0.005]. The differences in LS means (95% CI) of LDX vs. placebo in 
PERMP-Attempted at 1.5 hours and 13 hours were 16.97 (9.39, 24.56) and 28.28 (21.51, 
3.04), respectively (both P < 0.001). The differences in LS means (95% CI) of LDX vs. 
placebo in PERMP-Correct at 1.5 hours and 13 hours were 19.10 (12.25, 25.94) and 
28.14 (21.46, 34.83), respectively (both P < 0.001). The differences in LS means (95% 
CI) of LDX vs. placebo in SKAMP-Attention at 1.5 hours and 13 hours were –0.43(-
0.62, -0.23) and -0.47 (-0.62, -0.31), respectively (both P < 0.001).3 
Clinical Global Impressions 
The CGI-Improvement score in the dose optimization phase for all subjects was 
rated as improved (64.6%) or much improved (35.4%).  During the crossover period 93 
(82.3%) of participants were improved on LDX (58.4% very much improved and 23.9% 
much improved) vs. 22 (19.5%) with placebo. Of those subjects, 81 (71.7%) were 
improved while receiving LDX but not placebo, while 10 subjects (8.8%) were improved 
20 
 
on placebo but not on LDX. In the end the difference between LDX and placebo 
treatment was statistically significant (P < 0.0001).3 
Adverse Effects 
During the dose optimization phase that included 129 participants, 110 (85.3%) of 
participants had an adverse event: affected lability 13 (10.1%), decreased appetite 61 
(47.3%), headache 22 (17.1%), insomnia 35 (27.1%), irritability 21 (16.3%) and upper 
abdominal pain 20 (15.5%). While in the crossover phase of 115 subjects 38 (33%) had 
an adverse effect. These included: affected lability 0 (0.0%), decreased appetite 7 (6.1%), 
headache 6 (5.2%), insomnia 5 (4.3%), irritability 1 (0.9%) and upper abdominal pain 2 
(1.7%). Compared to placebo in the crossover phase 22 (19.1%) had adverse effects 
including: affected lability 1 (0.9%), decreased appetite 1 (0.9%), headache 2 (1.7%), 
insomnia 0 (0.0%), irritability 1 (0.9%) and upper abdominal pain 3 (2.6%). (Table IV)3 
Study D 
Findling et al, conducted the first long term, open label, multicenter, single arm 
study to evaluate children on maintenance doses of LDX for 11 months (Table II). 
Funding and support of this study was provided by shire development Inc. 272 
participants were titrated to LDX 30, 50 or 70mg a day over 4 weeks and then put on a 
maintenance dose based on titration. Of these 272 participants, 271 had participated in 
previous double-blinded trials of LDX within the past 7 days. Over time, the 
effectiveness of the dose was evaluated once monthly by the ADHD Rating Scale 
(ADHD-RS).  
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Primary Efficacy 
The mean ADHD-RS total score change from baseline was -27.2 ± 13.0 points in 
the population intended to treat a greater than 60% change from baseline (P < 0.0001). 
The mean ADHD-RS inattentive subscale score at endpoint changed -13.4 ± 7.0 points, 
again a 60% change from baseline (P < 0.0001). Lastly the ADHD-RS hyperactivity 
score at endpoint changed -13.8 ± 7.0 points a 66% change from baseline (P < 0.0001).4 
Secondary Efficacy 
The CGI Improvement scale rated 81.1% of subjects in the population intended to 
treat were rated as improved at the end of the study. The percentage of subjects who 
improved increased weekly during the 4- week dose titration period (51.5% at week 1, 
75.7% at week 2, 84.6% at week 3); to 90.0% by the time of dose stabilization at week 4. 
Thereafter, the percentage of subjects who improved remained at 90% for each monthly 
assessment and was 95.9% for subjects completing 12 months of treatment. 4 
Adverse Effects 
Over the course of the study 213 (78%) of the 272 participants experienced 
adverse effects, 97.5% of which were mild to moderate. (Table IV) The majority of these 
occurred in the first 4 weeks in >5% of the study population. These adverse events were 
reported as: decreased appetite 90 (33%), headache 48 (18), weight decrease 48 (18%), 
insomnia 47 (17%), upper abdominal pain 29 (11%), upper respiratory tract infection 29 
(11%), irritability 28 (10%), nasopharyngitis 26 (10%), vomiting 23 (9%), cough 19 (7%) 
and influenza 16 (6%).The most common reasons given for discontinuation (>1%) were 
22 
 
aggression, irritability and decreased appetite (n = 3 each; 1.1%). Insomnia (70mg/day = 
17%, 50mg/day = 9% and 30mg/day = 4%) and vomiting (70mg/day = 6%, 50mg/day = 
4% and 30mg/day = 3%) occurred more often in the patients receiving higher doses. 
Height increased an average 1.5 inches (P<0.05) and subject weight increased an average 
0.6 pounds (P = NS vs. baseline). When height and weight was normalized using z-
scores, which took expected growth into consideration, the average changes in z-scores 
for height and weight at endpoint were -0.08 (P<0.05 vs. baseline) and -0.40 (P = NS vs. 
baseline).The age and sex normalized mean change in weight from baseline in percentile 
was -13.4 over 1 year (average percentile at baseline and 12 months were 60.6 and 47.2, 
respectively). There were no clinically significant changes observed in laboratory values 
or finding from physical examinations. 4 
Discussion 
Lisdexamfetamine Dimesylate (LDX) is the latest medication approved by the 
FDA for the treatment of ADHD in children ages 6-12. As with any new ground breaking 
medication there continues to be a need for further evaluation and long term assessment. 
The initial studies have shown results positive for primary and secondary efficacy 
throughout the day with once daily dosing. The clinical trials revealed areas of study 
design that need improvement and concepts that require further evaluation. In a clinical 
trial, children are a very difficult population to study, especially long term. There are 
many concerns in studies involving children. They are more difficult to follow long term, 
parents don’t want their children to be treated with placebo and be consequently 
uncontrolled and there are ethical considerations. 
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Pharmaceutical Bias 
All of these research articles were sponsored by pharmaceutical companies which 
can lead to a major bias in how the literature is compiled, presented and marketed. Dr. 
Biederman’s research (Study A and B) was supported by New River Pharmaceuticals 
INC., and Shire Development Inc.1 He received research support from various 
pharmaceutical companies including, Abbott Laboratories, AstraZeneca Pharmaceuticals 
and Eli Lilly and company.1 Dr. Biederman is a member of Cephalon Inc., Eli Lilly and 
Company, McNeil, Novartis Pharmaceuticals Corporation, Shire and UCB Pharma, Inc. 
speaker’s bureaus.1 He is also a member of the advisory boards of the following 
pharmaceutical companies: Cephalon Inc.,Eli Lilly and Company, Janssen Pharmaceutica 
Products LP, McNeil, Novartis Pharmaceuticals Corporation and Shire.1 Dr. Findling 
(Study A and D) is also a member of similar pharmaceutical advisory boards. For Study 
D he received research support from Shire Development Inc. Study C was again funded 
by Shire Development Inc and statistical support was provided by a former Shire 
Development Inc. employee.3  
This weakens the credibility of these studies because they would be less likely to 
be critical of their employers and would have personal benefit in the outcomes. 
Therefore, all results should be reviewed with skepticism and the benefit of the 
pharmaceutical companies in mind.  
Efficacy 
The reviewed efficacy of LDX showed significant clinical improvement in 
ADHD symptoms when compared to placebo in children 6-12. Biederman et al (study A) 
showed improvement not only in the first week of treatment but the primary benefits 
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were continued on throughout the length of the study (6 weeks) as concluded from the 
ADHD-RS-IV score. Biederman et al (Study B), primary efficacy improvements were 
shown in SKAMP, PERMP and CGI scores (see table III) with the LDX group over 12 
hours post-dose when compared with placebo. Wigal et al (Study C), demonstrated the 
onset of action for LDX at 1.5 hours and duration of efficacy up to 13 hours post dose 
compared to placebo. This study also showed the distinct improvement and continuous 
effect on attention, behavior and math scores. Secondary efficacy showed 
parents/guardians noticing considerable improvement in their child’s ADHD symptoms, 
throughout the day with single dosing when compared to placebo. Overall these studies 
showed improvement on the various ADHD symptoms assessment scales when measured 
throughout the day at home and at school.  
This improvement of ADHD symptoms throughout the day supports the idea that 
the gradual release of d-amphetamine from LDX after a single dose provides an extended 
duration of action that would be sufficient for once daily dosing. This once daily dosing 
is a critical advantage for the management of children ages 6-12 with ADHD because of 
their forgetfulness and distractibility which can make it difficult to remember to take 
multiple doses daily. The consistency in efficacy over 13 hours was shown to avoid peaks 
and troughs throughout the day which is common with other stimulant medications. This 
consistency in medication may help relieve the frustration that comes with multiple 
dosing, peaks and troughs in medication release, not only for the patient, but for family 
and teachers. Well controlled ADHD symptoms will help children build normal, healthy, 
relationships; avoid struggles in the classroom and at home due to inattention, 
hyperactivity and impulsivity.  
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Tolerability 
The tolerability profile across these studies are very similar and  most reported 
treatment related adverse effects happened in the first week of treatment with dose 
titration, improved with time and were classified as mild to moderate. Study A escalated 
the doses of LDX faster than clinically recommended during dose titration. This 
escalation to most effective dose over a short period of time could have contributed to the 
amount (LDX 30mg = 72%, LDX 50mg = 68%, LDX = 84% and placebo = 47%) of 
adverse effects. More than 95% of these symptoms were mild to moderate, which is 
characteristic of stimulants. In Study B, regarding tolerability the open label dose 
optimization of MAS XR may have resulted in improved tolerability due to exposure to a 
stimulant prior to treatment. Therefore, the doses of MAS-XR may limit the conclusions 
regarding tolerability of LDX. The most common adverse effects across the studies were: 
anorexia, headache, insomnia, irritability and abdominal pain (Table IV). Each article 
notes that the adverse effect profile among these studies is similar and consistent with 
other currently marketed stimulants. Although, there is no direct comparisons shown in 
any of the literature. Further statistical comparison of these “similar adverse effects” and 
occurrences would be helpful when deciding which stimulant to prescribe and to possibly 
show one stimulant or class of ADHD medication to be more tolerable. 
Compliance can be an issue with regards to tolerability. In study A, only 84% of 
participants were compliant for 4 weeks.1 With children ages 6-12 you are likely to have 
parents/guardians or the school faculty administering the medication, rather than child. 
This makes compliance measurements difficult by adding a second party to administer 
the medication and can affect tolerability if doses are being missed, skipped or given late 
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in the day. Also a child may say they took the medication when they didn’t and parents 
may not admit to missing a dose due to being labeled as negligent.  This compliance issue 
can affect the tolerability results especially with a once daily dosing that is designed as an 
extended release. 
The class of medication that LDX is assigned to, has a warning of serious 
cardiovascular adverse effects, precaution and proper judgment should be used when 
treating children with stimulants for ADHD. It should be well understood that LDX has 
not been proven to cause serious cardiovascular adverse effects, but there is lack of an 
appropriate study to evaluate this. Cardiac disorders were exclusion criteria for all four 
studies. Therefore, any child with a cardiovascular condition should not take LDX. It 
would seem that it would have been important to address this serious risk directly which 
one study (study D) did. The other three studies were content to rely on a more mere 
mention under exclusion criteria. 
Study D claimed a consistency with the other medications in its class that there 
was a slowing in growth rate measured by body weight when compared to appropriate 
age and sex controls. Since this is a primary concern of parents and providers, it would be 
beneficial if LDX and slowing growth rate was analyzed further. Perhaps in regards to 
why pharmacologically LDX causes slow growth, at what doses is there a greater risk, 
clear comparison of children taking LDX and children of same age growth, and a clear 
comparison of slow growth rates with LDX use vs. other stimulant use.  
Additionally, anorexia is a common adverse effect of LDX which is classified as a 
mild to moderate effect. If a child develops anorexia from LDX this will most likely slow 
their growth, and lead to discontinuation of the medication. Should anorexia really be 
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considered a mild to moderate adverse effect if it can lead to slowing in growth rate and 
discontinuation of the medication? The impact, severity and comparison between long 
term ADHD medications regarding slowing of growth rate is difficult to study due to the 
population being studied, population size and avoidance of exposure to harm. There 
seems to be a lack of data regarding LDX and slowing growth rate. Therefore, growth 
should always be measured routinely among patients taking stimulants. Only one study 
(study D) compared growth rates based on the Centers for Disease Control and 
Prevention Growth Chart of height, weight and gender to evaluate the problem. 
Long term efficacy and tolerability 
The long term efficacies of medications in children are difficult to assess. In this 
case evaluating long term effects of LDX compared to placebo in children ages 6-12 was 
a challenge and revealed several limitations. Findling et al (study D), was the first long 
term study of LDX in children ages 6-12 versus placebo. This study showed that LDX 
treatment resulted in statistically and clinically significant improvements in the ADHD-
RS total score during the titration period and the 11 month maintenance period.4 LDX 
was shown to be well tolerated long term, with only mild to moderate adverse effects for 
up to 12 months of treatment.  
Two very important factors of limitation in this study should be considered when 
interpreting the results. The side effect profile used in study D did not use a structured 
adverse effect assessment, they used and open ended inquiry and observation which can 
limit the validity of the adverse effects or include unrelated effects.4 Also, the majority of 
participants had received LDX in recent previous studies which added a bias to the long 
term tolerability. It is likely that those who had adverse events in previous treatments had 
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discontinued and were not included in the long term study. This can cause a bias in the 
low rates of adverse effects reported in Study C, resulting in a bias toward the use of 
LDX in individuals with acceptable levels of known tolerability. This could possibly 
conclude there is an unknown tolerability of patients who have never been exposed to 
LDX. Since this is a new drug and there has not been much exposure the majority of your 
population is going to be unexposed to LDX. This bias may cause hesitation when 
prescribing the medication because tolerability is such a large factor when considering 
long term use.  
Long term treatment for ADHD in children ages 6-12 with LDX will need to be 
further studied and evaluated in precise detail. LDX is lacking solid information 
regarding long term efficacy and adverse effects which may make this medication 
difficult to prescribe because of the unknown tolerability of the actual populations being 
treated.  
Limitations 
A major limitation to these studies is when evaluating efficacy of LDX 
researchers have excluded children with psychiatric comorbidities. Children with ADHD 
are more common to have a comorbid psychiatric condition, diagnosed or undiagnosed.6 
Also, a comorbid condition is present in as many as two thirds of clinically referred 
children with ADHD; these studies have excluded a extremely large patient population in 
the evaluation of efficacy and tolerability of LDX.6. This exclusion does pose a problem 
when prescribing LDX to those patients with comorbid diagnoses or possibly 
undiagnosed comorbidities.  It would be helpful to clinicians if studies included children 
with comorbid conditions and evaluate efficacy and tolerability of LDX. This would be a 
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serve as a more realistic approach to what clinicians are seeing and treating in their 
offices. The current studies will most likely serve as a backbone to researchers when they 
branch out and include a wider population into their further studies of LDX. 
There are no studies in children ages 6-12 that evaluate the possibility of future 
addiction or abuse in children who take LDX. Addiction is a main concern for parents 
considering putting their children on stimulants, especially long term. Although, there 
have been studies in adults concerning addiction there have been no studies in children. 
Again this is a disadvantage of LDX being such a new drug on the market and there are 
difficulties following up with children exposed to LDX and deciphering if the factors that 
lead to addiction or abuse were potentiated by LDX. 
Limitations of Biederman et al (Study A), include the 4 week duration which 
limits the evidence of efficacy and tolerability that is generally required in the treatment 
of ADHD. In addition several of the findings were based on parental assessments (CPRS 
rating) which can be biased or subjective. There was no study of children in a classroom 
environment. Again, doses were escalated too quickly during titration which is unlike 
clinical practice, therefore, contributing to adverse effects and possibly affecting 
efficacy.1  
Regarding limitations of Biederman et al (Study B), the short duration of the 
study did not help provide results regarding long term efficacy and tolerability of LDX at 
home or in the classroom. The children studied all had been previously exposed and 
responsive to stimulants. Therefore, this study’s conclusions exclude the patients who 
have not been treated with stimulants in the past. The prior stimulant use also causes a 
bias regarding the tolerability profile of LDX in this study. The open label dose 
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optimization use of MAS XR may have resulted in improved tolerability in the double 
blind period in this study. The use of MAX-XR limited the conclusions regarding 
tolerability of LDX. Finally, due to study size, researchers cannot determine the benefit 
concerning gender, race or age.2 
Limitations of Wigal et al (Study C) were consistent with laboratory school study 
designs, in that the short treatment duration and assessment phases provide an 
underestimation of the number and severity of adverse effects seen with lengthier studies 
and under long term use. Also, the results were only measured for 13 hours a day and no 
measurements 13 hours post dose were taken to assess for change in symptoms post 
dose.3 
Studies in the future should contain evaluation of LDX efficacy in relieving 
ADHD symptoms past 13 hours. They need to include patients with psychiatric 
comorbidities to better represent the ADHD populations being treated. The short and long 
term efficacy and tolerability of LDX need to be further assessed among those patients 
who have not taken stimulants in the past. Also long term studies that appropriately 
evaluate tolerability without bias are needed.  
Conclusion 
The symptoms of ADHD are unpredictable; they can extend beyond the school 
day and continue into afterschool activities and family interactions.  The successful 
management of ADHD requires several combinations of treatment to be most successful. 
The first prodrug stimulant, Lisdexamfetamine Dimesylate (LDX) is another step forward 
in improving medication treatment for children with ADHD. The benefits of once daily 
dosing and suggested efficacy over the course of a school day and into the early evening 
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are areas that have been a challenge among other ADHD medications. This makes LDX a 
positive step forward in the treatment of ADHD for patients and their families. 
Since ADHD is generally controlled with long term medication management, 
further long term studies will be valuable to confirm the therapeutic success of LDX. 
Studies should be broadened to cover a more representative population for example, 
children with psychiatric comorbidities or children with no prior exposure to stimulants. 
A better analysis should be done regarding growth and weight rates while on LDX and 
LDX should ultimately be compared to drugs both within and outside its class. While the 
studies address adverse effects as similar to those of the other stimulants, they do not 
outline what the adverse effects actually are. The latter may be due to the fact that these 
studies may have an interest in the outcome due to the inherent bias from pharmaceutical 
companies and too much attention to adverse effects would weaken the case for their 
drug. Future studies should be conducted by objective parties. Although, further 
evaluation and long term assessment needs to be done, these studies suggest that LDX is 
a promising prodrug stimulant when compared to placebo for the treatment of ADHD.  
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Table I 
DSM-IV criteria for attention deficit hyperactivity disorder 5 
1. Six (or more) of the following symptoms of inattention have persisted for at least six 
months to a degree that is maladaptive and inconsistent with developmental level:  
• Inattention 
o Often fails to give close attention to details or makes careless mistakes in 
schoolwork, work or other activities  
o Often has difficulty sustaining attention in tasks or play activities  
o Often does not seem to listen when spoken to directly  
o Often does not follow through on instructions and fails to finish 
schoolwork, chores, or duties in the workplace (not due to oppositional 
behavior or failure to understand instructions)  
o Often has difficulty organizing tasks and activities  
o Often avoids, dislikes, or is reluctant to engage in tasks that require 
sustained mental effort (such as schoolwork or homework)  
o Often loses things necessary for tasks or activities (e.g., toys, school 
assignments, pencils, books, or tools)  
o Is often easily distracted by extraneous stimuli  
o Is often forgetful in daily activities  
 
2. Six (or more) of the following symptoms of hyperactivity-impulsivity have persisted 
for at least six months to a degree that is maladaptive and inconsistent with 
developmental level:  
• Hyperactivity  
o Often fidgets with hands or feet or squirms in seat  
o Often leaves seat in classroom or in other situations in which remaining 
seated is expected  
o Often runs about or climbs excessively in situations in which it is 
inappropriate (in adolescents, or adults, may be limited to subjective 
feelings of restlessness)  
o Often has difficulty playing or engaging in leisure activities quietly  
o Is often "on the go" or often acts as if "driven by a motor"  
o Often talks excessively  
• Impulsivity  
o Often blurts out answers before questions have been completed  
o Often has difficulty awaiting turn  
o Often interrupts or intrudes on others (e.g., butts into conversations or games)  
• Additional criteria  
o Some hyperactive-impulsive or inattentive symptoms that caused impairment 
were present before age seven years. 
o Some impairment from the symptoms is present in two or more settings (e.g., 
at school [or work] and at home). 
o There must be clear evidence of clinically significant impairment in social, 
academic or occupational functioning. 
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Table II 
Selected Studies of Lisdexamfetamine Dimesylate for attention deficit hyperactivity disorder in children ages 6-12 
Authors, Title, Publication # Subjects Regime Study Type Validity 
(Jadad score) 
Results 
Study A 
Biederman, J. et al 
Efficacy and tolerability of 
lisdexamfetamine dimesylate 
(NRP-104) in children with 
attention-deficit/hyperactivity 
disorder: a phase III, multicenter, 
randomized, double-blind, forced-
dose, parallel-group study. 
2007 
N=290 
LDX 30mg=71 
LDX50mg=74 
LDX 70mg=73 
Placebo=72 
 
LDX 
Vs. 
Placebo 
A phase III, multicenter, 
randomized, double-
blind, forced-dose, 
parallel-group study 
Score:5 Treatment once daily with 30 
to 70 mg of the prodrug LDX 
appeared to be effective and 
had a tolerability profile 
similar to those of currently 
marketed extended-release 
stimulants.1 
Study B 
Biederman, J. et al. 
Lisdexamfetamine dimesylate and 
mixed amphetamine salts 
extended-release in children with 
ADHD. 
2007 
N=52 
Cohort A=10 
Cohort B=17 
Cohort C=25 
LDX 
Vs. 
Placebo 
A double-blind, placebo-
controlled, crossover 
analog classroom study 
Score:4 In a laboratory classroom 
environment, LDX 
significantly improved 
ADHD symptoms versus 
placebo in school-age 
children with ADHD.2 
Study C 
Wigal, S.B. et al. 
A 13-hour laboratory school study 
of Lisdexamfetamine dimesylate 
in school-aged children with 
attention-deficit/hyperactivity 
disorder. 
2009 
N=129 
LDX 30mg=58 
LDX50mg=50 
LDX 70mg=21 
 
LDX 
Vs. 
Placebo 
A Phase IIIb, 
Randomized, Double-
Blind, Multi-Center, 
Placebo-Controlled, 
Dose-Optimization, 
Cross-Over, Analog 
Classroom Study 
Score:4 In children (6 to 12 years) 
with ADHD, efficacy of 
LDX was maintained from 
1.5 hours up to 13.0 hours. 
LDX was generally well 
tolerated, resulting in typical 
stimulant AEs.3 
Study D 
Findling, R.L. et al. 
Long-term effectiveness and 
safety of lisdexamfetamine 
dimesylate in school-aged 
children with ADHD. 
2008 
N=272 LDX 
 
A open-label, 
multicenter, single-arm 
study 
 Long-term 30, 50, and 70 
mg/day LDX was generally 
well tolerated and effective 
in children with ADHD.4 
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Table III  
ADHD rating scales used to evaluate LDX 
ADHD rating scales 
used in studies A-D 
Appropriat
e for 
Administer
ed by 
Assessing Measurement scale Completion 
time 
Evaluated in 
study 
ADHD-RS-IV Attention 
deficit hyperactivity 
disorder-rating scale-
fourth edition  
Children 
and 
adolescence 
ages 3-17 
Parents 
(home 
version), 
Teachers 
(school 
version) 
Treatment response 
based on DSM-IV 
criteria 
18 items scored. 
Total score range:  
0-54 
No symptoms (0) –  
The most severe 
symptoms (54). 
5-10 minutes A, C & D 
CGI Severity 
Clinical Global 
Impression 
All patients Clinicians Treatment response 
relative to baseline 
Scale 1-7 
Normal, not ill at all 
(1) - the most 
extremely ill patients 
(7) 
5 minutes A, B, C & D 
CGI Improvement 
Clinical Global 
Impression 
All patients Clinicians Treatment response 
relative to baseline 
Scale 1-7  
Very much 
improved (1) - Very 
much worse (7) 
 
5 minutes A, B, C & D 
CPRS-R (short 
version) 
Conners’ parent rating 
scale revised 
Children 
and 
adolescents 
ages 3–17 
Parents, 
teachers or 
self 
assessment 
ADHD-severity: 
oppositional, 
cognitive problems, 
inattention,  
hyperactivity 
Scale 0-4,  
Not true at all (0) - 
Very true (4) 
Short version 
5-10 minutes 
 
Long version 
15-20 minutes 
A 
PERMP Attempted 
and Completed 
Permanent Product 
Measure of Performance 
Children 
and 
adolescents 
ages 3–17 
Teachers 
(math test) 
Rate of behavior 
and response to 
stimulant, dose and 
duration. 
(# of times behavior 
occurred) / (# of 
opportunities) = % 
of behavior 
occurrences 
10 minutes B & C 
SKAMP Deportment 
and Attention 
Swanson, Kotkin, Agler, 
M-Flynn, and Pelham  
All patients Teachers Primary efficacy of 
medication and 
impairment in 
classroom behavior 
Scale 0-6 
No symptoms (0) -  
Severe symptoms 
(6) 
5-10 minutes B & C  
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Table IV 
Adverse effects of all LDX doses in each study group 
 
Adverse Effect 
Study A 
All LDX Doses 
(n = 218) 
Study B 
All LDX Doses 
(n = 50 ) 
Study C 
All LDX Doses 
(n =129 ) 
Study D 
All LDX Doses 
(n = 272 ) 
Any events,  
No. % AE 
162 (74.3) 9 (18.0) 110 (85.3) 213 (78) 
Decreased 
appetite 
85 (39.0) 3(6.0) 61 (47.3) 90 (33) 
Insomnia 41 (18.8) 4(8.0) 35 (27.1) 47 (17) 
Upper abdominal 
pain 
26 (11.9) 0(0.0) 20 (15.5) 29 (11) 
Irritability 21 (9.6) 0(0.0) 21 (16.3) 28 (10) 
Headache 26 (11.9) NR 22 (17.1) 48 (18) 
Dizziness 11 (5.0) NR NR NR 
Vomiting 19 (8.7) 0(0.0) NR 23 (9) 
Nasopharyngitis 11 (5.0) NR NR 26 (10) 
Weight loss 20 (9.2) 2(4.0) NR 48 (18) 
Nasal congestion 3 (1.4) NR NR NR 
Nausea 13 (6.0) NR NR NR 
Cough 3 (1.4) NR NR 19 (7) 
Dry mouth 10 (4.6) NR NR NR 
Upper respiratory 
tract infection 
NR 1(2.0) NR 29 (11) 
NR = not reported     
LDX = Lisdexamfetamine Dimesylate 
36 
 
References 
1. Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of 
lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A 
phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 
2007;29:450-463.  
2. Biederman J, Boellner SW, Childress A, Lopez FA, Krishnan S, Zhang Y. Lisdexamfetamine 
dimesylate and mixed amphetamine salts extended-release in children with ADHD: A double-blind, 
placebo-controlled, crossover analog classroom study. Biol Psychiatry. 2007;62:970-976.  
3. Wigal SB, Kollins SH, Childress AC, Squires L, the 311 Study Group. A 13-hour laboratory school 
study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity 
disorder. Child Adolesc Psychiatry Ment Health. 2009;3:17.  
4. Findling RL, Childress AC, Krishnan S, McGough JJ. Long-term effectiveness and safety of 
lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. 
CNS Spectr. 2008;13:614-620.  
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition: Diagnostic Criteria for Attention Deficit Hyperactivity Disorder. Available at: 
http://www.psychiatryonline.com. Accessed July 21, 2009.  
6. Dulcan M. Practice parameters for the assessment and treatment of children, adolescents, and adults 
with attention-deficit/hyperactivity disorder. american academy of child and adolescent psychiatry. 
Journal of the American Academy of Child & Adolescent Psychiatry. 1997;36:85S-121S.  
37 
 
7. National Institute of Health. National Institute of Mental Health, Attention Deficit Hyperactivity 
Disorder. Available at: http://www.nimh.nih.gov/health/publications/attention-deficit-hyperactivity-
disorder/complete-index.shtml. Accessed July 6, 2009.  
8. Pliszka SR, Crismon ML, Hughes CW, et al. The texas children's medication algorithm project: 
Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder.[see 
comment]. J Am Acad Child Adolesc Psychiatry. 2006;45:642-657.  
9. Shire US Inc. Vyvanse [package insert]. Available at: 
http://vyvanse.com/pdf/prescribing_information.pdf. Accessed July 6, 2009.  
10. Blick SK, Keating GM. Lisdexamfetamine. Paediatr Drugs. 2007;9:129-135.  
11. Elia J, Easley C, Kirkpatrick P. Lisdexamfetamine dimesylate. Nat Rev Drug Discov. 2007;6:343-
344.  
 
